185 related articles for article (PubMed ID: 11895892)
1. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
Richon VM; O'Brien JP
Clin Cancer Res; 2002 Mar; 8(3):662-4. PubMed ID: 11895892
[No Abstract] [Full Text] [Related]
2. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
Weidle UH; Grossmann A
Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
[TBL] [Abstract][Full Text] [Related]
3. [Histone deacetylase inhibitors--new anticancer agents?].
Yoshida M; Horinouchi S
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1090-5. PubMed ID: 10771678
[No Abstract] [Full Text] [Related]
4. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
6. [[Inhibitors of histone deacetylase as new agents for prevention and treatment of cancer] ].
Jung M
Pharm Unserer Zeit; 2000 Nov; 29(6):385-8. PubMed ID: 11199916
[No Abstract] [Full Text] [Related]
7. FR-901228 Fujisawa/National Cancer Institute.
Vigushin DM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1396-402. PubMed ID: 12498018
[TBL] [Abstract][Full Text] [Related]
8. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors.
Kelly WK
Clin Adv Hematol Oncol; 2004 Nov; 2(11):722-3. PubMed ID: 16163258
[No Abstract] [Full Text] [Related]
11. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S; Ho AD; Mahlknecht U
Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
[TBL] [Abstract][Full Text] [Related]
12. Clinical studies of histone deacetylase inhibitors.
Prince HM; Bishton MJ; Harrison SJ
Clin Cancer Res; 2009 Jun; 15(12):3958-69. PubMed ID: 19509172
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors: overview and perspectives.
Dokmanovic M; Clarke C; Marks PA
Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
15. A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
Yamamoto S; Yamano T; Tanaka M; Hoon DS; Takao S; Morishita R; Aikou T; Kaneda Y
Cancer Gene Ther; 2003 Mar; 10(3):179-86. PubMed ID: 12637938
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors as novel anti-inflammatory agents.
Adcock IM
Curr Opin Investig Drugs; 2006 Nov; 7(11):966-73. PubMed ID: 17117583
[TBL] [Abstract][Full Text] [Related]
18. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.
Furumai R; Matsuyama A; Kobashi N; Lee KH; Nishiyama M; Nakajima H; Tanaka A; Komatsu Y; Nishino N; Yoshida M; Horinouchi S
Cancer Res; 2002 Sep; 62(17):4916-21. PubMed ID: 12208741
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin.
Cao H; Stamatoyannopoulos G
Am J Hematol; 2006 Dec; 81(12):981-3. PubMed ID: 16888791
[TBL] [Abstract][Full Text] [Related]
20. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]